Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumours or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Alisertib (Primary) ; Esomeprazole; Rifampicin
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 29 Sep 2016 Status changed from active, no longer recruiting to completed.
- 29 Sep 2015 Interim results (n=29) presented at the European Cancer Congress 2015.
- 29 Jan 2015 Planned End Date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.